

Aragen Life Sciences receives Science Based Targets initiative (SBTi) approval for its greenhouse gas emission reduction targets

First Indian CRDMO to receive SBTi approval

Hyderabad, India, 16 September, 2024:

Aragen Life Sciences, a leading global provider of contract research, development, and manufacturing services for the life sciences industries announced that it has received approval from the UK based Science Based Targets initiative (SBTi) for its near-term and net-zero sustainability targets. SBTi has validated Aragen's greenhouse gas emission reduction targets to conform with its criteria and recommendations, as outlined in Criteria version 5.1.

Aragen's approved targets:

- Overall Net-Zero Target: committed to achieving net-zero greenhouse gas emissions across its value chain by FY2050
- Near-Term Targets: Reducing absolute Scope 1, 2 and 3 GHG emissions by 50.4% by FY2033 (base year FY2023)
- Long-Term Targets: Reducing absolute Scope 1, 2, and 3 GHG emissions by 90% by FY2050 (base year FY2023)

Commenting on the approval, **Manni Kantipudi, CEO, Aragen Life Sciences** said, *"This validation by the SBTi is more than just a recognition of our efforts; it is a critical step forward in our sustainability journey. These targets underscore our dedication to innovation, collaboration, and transparency in a holistic manner, while ensuring sustainability measures are in place as we work with the 400+ customers globally. We are determined to make a meaningful and measurable impact in our fight against climate change."*

Shivaji Jadhav, VP & Head, EHS & Sustainability at Aragen added, *"This approval is an endorsement of the rigorous efforts we've put into our sustainability initiatives. It underscores our responsibility to our planet and reinforces our commitment to leading by example in the industry."*

The SBTi targets provide a scientifically backed framework for reducing greenhouse gas emissions, in line with the 2015 Paris agreement. This validation marks a historic milestone for Aragen, positioning the company as a leader in climate action within the life sciences sector. It reflects Aragen's unwavering commitment to reducing its carbon footprint in a meaningful and measurable way and contributing to the collective fight against climate change.

About Aragen:

Aragen Life Sciences is a leading R&D and manufacturing solutions provider to the global life sciences industries. It offers a range of solutions across the drug development continuum to advance small and large-molecule programs. The Company operates through a global network of eight sites with a team of ~4,400 employees and 450+ PhDs. Its expertise and experience have enabled over 400 customers to advance their research programs from early discovery through development and commercialization. Aragen's innovative mindset, infrastructure, flexible business models, clear purpose, and proprietary project management platform have enabled it to effectively scale and service large pharma, biotech, agrochemical, and animal health industries globally. Visit www.aragen.com for more details.